Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.

Pharma companies hope promises for more domestic investment could spare them from sector-specific tariffs. (Shutterstock)
Key Takeaways
  • Drug manufacturers and investors want more detail on US government plans for pharmaceutical-sector tariffs.

During the latest round of quarterly sales and earnings updates, drug manufacturers signaled they are well positioned to absorb the...

More from Manufacturing

More from Market Access